A5045732633- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
- Family Support in Illness
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Health Systems, Economic Evaluations, Quality of Life
- Genetic factors in colorectal cancer
- T-cell and Retrovirus Studies
- Platelet Disorders and Treatments
- Biosimilars and Bioanalytical Methods
- Cancer Immunotherapy and Biomarkers
- Lymphadenopathy Diagnosis and Analysis
- Eosinophilic Disorders and Syndromes
- Vascular Tumors and Angiosarcomas
- Multiple Myeloma Research and Treatments
- Prenatal Screening and Diagnostics
- Protein Degradation and Inhibitors
- Blood Pressure and Hypertension Studies
- Extracellular vesicles in disease
Radboud University Medical Center
2016-2025
Radboud University Nijmegen
2016-2025
Hovon
2023
University Medical Center
2011-2022
University Hospital and Clinics
2011-2012
Máxima Medisch Centrum
2006
MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis many studies. The impact MYC-R on may be influenced by the partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated cohort patients through Lunenburg Lymphoma Biomarker Consortium to validate prognostic significance (single-, double-, triple-hit status) DLBCL within context gene.The study included histologically confirmed morphology derived...
Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later in life. The aim this study was examine differences HRQoL between AYA lymphoma survivors normative population determine sociodemographic, clinical long-term symptom-related factors associated HRQoL.This part longitudinal, population-based survey among diagnosed 1999 2012. survivor sample...
Abstract Although the genomic and immune microenvironmental landscape of follicular lymphoma (FL) has been extensively investigated, little is known about potential biological differences between stage I III/IV disease. Using next-generation sequencing immunohistochemistry, 82 FL nodal cases were analyzed compared with 139 cases. Many similarities in mutations, chromosomal copy number aberrations, cell populations detected. However, there also significant features. CD8+ T cells (P = .02)...
Aims Follicular lymphoma (FL) is characterised by significant heterogeneity in both the clinical trajectories and molecular profiles. This study aimed to investigate clonal dynamics FL analysing mutation profiles at various time points during disease course including histological transformation (HT), gain insight into mutational changes over time. Methods We retrospectively analysed 76 biopsies from 25 patients, 13 cases with three or more 12 subsequent HT. Hybrid capture-based...
In follicular lymphoma, studies addressing the prognostic value of microenvironment-related immunohistochemical markers and tumor cell-related genetic have yielded conflicting results, precluding implementation in practice. Therefore, Lunenburg Lymphoma Biomarker Consortium performed a validation study evaluating published markers. To maximize sensitivity, an end spectrum design was applied for 122 uniformly immunochemotherapy-treated lymphoma patients retrieved from international trials...
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1–2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy effective but associated considerable toxicity. In this observational study, we compared real-world efficacy, toxicity, and costs four frequently employed treatment strategies lymphoma: the Lymphome Malins (LMB), Berlin-Frankfurt-Münster (BFM), HOVON, CODOX-M/IVAC regimens. We collected data from 147 patients treated in eight referral...
In primary central nervous system lymphoma (PCNSL), small enhancing lesions can persist after treatment. It is unknown whether a difference in response category (complete [CR], complete unconfirmed [CRu], or partial [PR]) reflects survival. We aimed to determine the value of radiology review on assessment and extent influenced progression-free and/or overall survival.All patients HOVON 105/ALLG NHL 24 study with at least baseline MRI one made for evaluation available were included. Tumor...
Summary Little is known about the long‐term health‐related quality of life (HRQoL) and persistence symptoms among patients with indolent non‐Hodgkin lymphoma (iNHL). This large population‐based longitudinal study therefore investigated HRQoL identified associated sociodemographic, clinical psychological factors. Patients diagnosed between 1999 2014 four or more months after diagnosis were invited to participate in a survey. Sociodemographic data obtained from Netherlands Cancer Registry. The...
To investigate the spectrum of mutations in 20 genes involved B-cell receptor and/or Toll-like signalling resulting activation nuclear factor-κB (NF-κB) nodal marginal zone lymphomas (NMZLs), follicular (FLs), and 11 cases lymphoma, unclassifiable (BCL-u).Nodal were diagnosed according to strict criteria, including expression at least one putative marker (MNDA IRTA1). Cases that showed features NMZL but did not fulfil all criteria included as BCL-u. All FLs required have a BCL2...
Abstract In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, Netherlands was one first countries to implement R-biosimilars, given lower costs compared with originator (R-originator). This study’s objective investigate whether overall survival (OS) patients DLBCL receiving R-biosimilars is similar treated R-originator. ≥18 years, diagnosed between 2014 and 2018, who received at least 1 cycle...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: BTK plays a central role in the B cell receptor (BCR) signaling pathway and is involved pathogenesis of several malignancies. While inhibition has been validated as an effective therapeutic strategy patients with malignancies, emerging patterns resistance intolerance limit utility covalent and/or non-covalent inhibitors later lines treatment. Novel therapeutics that can overcome mutations may represent alternative treatment...
The purpose of the study is to examine differences in perceived impact cancer (IOC) between adolescents and young adults (AYAs; 18–35 years at diagnosis), (36–64 years) elderly (65–84 with a history (non-)Hodgkin lymphoma. Furthermore, investigate association socio-demographic, clinical psychological characteristics IOC; IOC health-related quality life (HRQoL) among AYAs only. This part population-based PROFILES registry survey lymphoma patients diagnosed 1999 2009. Patients (n = 1.281) were...
Large B cell lymphoma with IRF4 rearrangement (LBCL-IRF4) is a new entity in the 2017 revised World Health Organisation (WHO) classification that was initially mainly reported children. After identification of 79-year-old patient, we assessed how often rearrangements can be detected adult diffuse large lymphomas (DLBCLs) which have to reclassified LBCL-IRF4 based on fluorescence in-situ hybridisation (FISH) for IRF4.With FISH, studied presence 238 were diagnosed as DLBCL according previous...
Abstract Background Studies on the efficacy of rituximab in primary CNS lymphoma (PCNSL) reported conflicting results. Our international randomized phase 3 study showed that addition to high-dose methotrexate, BCNU, teniposide, and prednisolone (MBVP) PCNSL was not efficacious short term. Here we present long-term results after a median follow-up 82.3 months. Methods One hundred ninety-nine eligible newly diagnosed, nonimmunocompromised patients with aged 18–70 years WHO performance status...